Tatva Chintan Pharma (TATVA) | Financial Analysis & Statements
Tatva Chintan Pharma Chem Limited Small-cap Basic Materials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.2B
Gross Profit
585.2M
50.07%
Operating Income
83.6M
7.15%
Net Income
66.5M
5.69%
EPS (Diluted)
₹2.84
Balance Sheet Metrics
Total Assets
8.4B
Total Liabilities
974.2M
Shareholders Equity
7.4B
Debt to Equity
0.13
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Tatva Chintan Pharma Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.8B | 3.9B | 4.2B | 4.3B | 3.0B |
| Cost of Goods Sold | 2.1B | 1.8B | 2.3B | 2.1B | 1.6B |
| Gross Profit | 1.7B | 2.1B | 1.9B | 2.2B | 1.4B |
| Gross Margin % | 45.3% | 53.0% | 44.3% | 51.8% | 46.7% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | 2.8M |
| Selling, General & Administrative | 316.1M | 284.0M | 338.3M | 374.4M | 214.5M |
| Other Operating Expenses | 540.2M | 554.9M | 421.3M | 446.1M | 244.4M |
| Total Operating Expenses | 856.2M | 838.9M | 759.7M | 820.5M | 461.7M |
| Operating Income | 69.1M | 441.2M | 587.4M | 1.0B | 600.4M |
| Operating Margin % | 1.8% | 11.3% | 14.0% | 23.4% | 20.2% |
| Non-Operating Items | |||||
| Interest Income | 4.9M | 32.8M | 53.3M | 46.7M | 3.6M |
| Interest Expense | 9.0M | 61.5M | 80.0M | 43.5M | 39.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 75.8M | 435.7M | 447.8M | 1.0B | 607.0M |
| Income Tax | 18.7M | 132.1M | -7.1M | 82.5M | 84.3M |
| Effective Tax Rate % | 24.6% | 30.3% | -1.6% | 7.9% | 13.9% |
| Net Income | 57.1M | 303.5M | 454.9M | 958.7M | 522.6M |
| Net Margin % | 1.5% | 7.8% | 10.8% | 22.2% | 17.6% |
| Key Metrics | |||||
| EBITDA | 361.8M | 754.2M | 661.0M | 1.2B | 714.7M |
| EPS (Basic) | ₹2.44 | ₹13.26 | ₹20.52 | ₹44.59 | ₹23.58 |
| EPS (Diluted) | ₹2.44 | ₹13.26 | ₹20.52 | ₹44.59 | ₹23.58 |
| Basic Shares Outstanding | 23392055 | 22889189 | 22165062 | 21499104 | 22165062 |
| Diluted Shares Outstanding | 23392055 | 22889189 | 22165062 | 21499104 | 22165062 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Tatva Chintan Pharma Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 113.7M | 353.0M | 273.6M | 630.2M | 44.8M |
| Short-term Investments | 3.3M | 103.6M | 138.5M | 8.0M | 37.8M |
| Accounts Receivable | 825.3M | 698.5M | 844.0M | 566.0M | 907.4M |
| Inventory | 1.3B | 1.5B | 1.6B | 1.7B | 720.2M |
| Other Current Assets | 380.0K | 7.0M | 5.9M | 4.2M | 131.1M |
| Total Current Assets | 2.7B | 3.0B | 3.1B | 4.4B | 1.8B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 551.5M | 462.1M | 169.0M | 115.9M | 1.2B |
| Goodwill | 59.0M | 39.6M | 4.8M | 3.2M | 950.0K |
| Intangible Assets | 59.0M | 39.6M | 4.8M | 3.2M | 950.0K |
| Long-term Investments | 0 | 0 | 0 | 0 | - |
| Other Non-Current Assets | 11.1M | 8.3M | 5.5M | 5.1M | 3.0M |
| Total Non-Current Assets | 5.7B | 5.2B | 4.5B | 2.2B | 1.3B |
| Total Assets | 8.4B | 8.2B | 7.6B | 6.6B | 3.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 326.9M | 450.3M | 321.9M | 445.1M | 474.8M |
| Short-term Debt | 363.9M | 136.3M | 1.7B | 1.1B | 634.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 190.4M | 123.2M | 76.6M | 185.4M | 64.9M |
| Total Current Liabilities | 960.3M | 796.6M | 2.4B | 1.7B | 1.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 0 | 6.4M | 42.3M | 131.1M | 267.6M |
| Deferred Tax Liabilities | - | - | - | 0 | 20.8M |
| Other Non-Current Liabilities | - | - | - | 170.0K | 14.3M |
| Total Non-Current Liabilities | 14.0M | 19.7M | 53.8M | 137.7M | 308.2M |
| Total Liabilities | 974.2M | 816.4M | 2.4B | 1.8B | 1.5B |
| Equity | |||||
| Common Stock | 233.9M | 233.9M | 221.6M | 221.6M | 200.9M |
| Retained Earnings | 3.1B | 3.1B | 2.8B | 2.4B | 1.5B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 7.4B | 7.4B | 5.1B | 4.7B | 1.7B |
| Key Metrics | |||||
| Total Debt | 363.9M | 142.7M | 1.7B | 1.2B | 902.5M |
| Working Capital | 1.7B | 2.2B | 735.6M | 2.6B | 662.4M |
Balance Sheet Composition
Tatva Chintan Pharma Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 75.8M | 435.7M | 447.8M | 1.0B | 607.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 52.6M | 242.7M | -126.7M | -742.2M | -546.8M |
| Operating Cash Flow | 145.9M | 714.0M | 396.6M | 302.1M | 97.9M |
| Investing Activities | |||||
| Capital Expenditures | -761.3M | -1.3B | -2.0B | -890.8M | -209.5M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | 0 | -99.0M | 0 | - | - |
| Investment Sales | 103.9M | 144.5M | 965.7M | - | 2.5M |
| Investing Cash Flow | -657.4M | -1.2B | -1.1B | -890.8M | -206.3M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -46.8M | -46.8M | -44.3M | - | -40.2M |
| Debt Issuance | 40.0K | 0 | 8.3M | 0 | 91.5M |
| Debt Repayment | -32.2M | -86.6M | -139.4M | -134.3M | -184.2M |
| Financing Cash Flow | 178.6M | 370.5M | 462.0M | 2.4B | -5.1M |
| Free Cash Flow | -516.0M | -304.7M | -1.8B | -689.3M | -14.8M |
| Net Change in Cash | -332.9M | -153.7M | -206.1M | 1.8B | -113.4M |
Cash Flow Trend
Tatva Chintan Pharma Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
93.92
Forward P/E
45.99
Price to Book
4.10
Price to Sales
6.45
PEG Ratio
0.01
Profitability Ratios
Profit Margin
6.83%
Operating Margin
12.50%
Return on Equity
0.77%
Return on Assets
0.68%
Financial Health
Current Ratio
1.95
Debt to Equity
11.00
Beta
0.34
Per Share Data
EPS (TTM)
₹14.07
Book Value per Share
₹322.54
Revenue per Share
₹205.22
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TATVA | 29.7B | 93.92 | 4.10 | 0.77% | 6.83% | 11.00 |
| Asian Paints | 2.4T | 62.11 | 12.16 | 18.28% | 11.10% | 17.61 |
| Pidilite Industries | 1.4T | 62.22 | 14.87 | 20.85% | 16.19% | 4.54 |
| Tanfac Industries | 49.6B | 66.26 | 14.61 | 28.25% | 10.85% | 9.28 |
| Gulf Oil Lubricants | 48.1B | 13.85 | 2.91 | 23.50% | 8.88% | 29.57 |
| Neogen Chemicals | 44.8B | 222.22 | 5.46 | 4.41% | 2.41% | 141.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.





